scholarly journals Reassessment of sst3Somatostatin Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-5

2012 ◽  
Vol 96 (4) ◽  
pp. 301-310 ◽  
Author(s):  
Amelie Lupp ◽  
Falko Nagel ◽  
Christian Doll ◽  
Christoph Röcken ◽  
Matthias Evert ◽  
...  
2008 ◽  
Vol 93 (11) ◽  
pp. 4519-4524 ◽  
Author(s):  
Thomas Fischer ◽  
Christian Doll ◽  
Stefan Jacobs ◽  
Angela Kolodziej ◽  
Ralf Stumm ◽  
...  

2011 ◽  
Vol 94 (3) ◽  
pp. 255-264 ◽  
Author(s):  
Amelie Lupp ◽  
Anna Hunder ◽  
Aline Petrich ◽  
Falko Nagel ◽  
Christian Doll ◽  
...  

Peptides ◽  
2015 ◽  
Vol 66 ◽  
pp. 19-25 ◽  
Author(s):  
Amelie Lupp ◽  
Anika Mann ◽  
Alexander Heeb ◽  
Daniel Kaemmerer ◽  
Jörg Sänger ◽  
...  

2013 ◽  
Vol 66 (12) ◽  
pp. 1051-1057 ◽  
Author(s):  
Sunil Badve ◽  
I Tudor Vladislav ◽  
Betsy Spaulding ◽  
Anna Strickland ◽  
Sylvia Hernandez ◽  
...  

AimsAssessment of hormone receptor expression is part of routine examination of every breast cancer. In this study, we report the characterisation of a novel rabbit monoclonal antibody, clone EP1, directed against oestrogen receptor (ER) α. Additionally, its immunohistochemical performance characteristics in archival tissues are evaluated in normal tissues and two distinct cohorts of breast cancer patients.MethodsComparative analyses between EP1 and the anti-ERα component of the ER/PR pharmDx kit (cocktail of mouse monoclonal antibody clones 1D5 and ER-2-123) and between EP1 and another commercially available rabbit monoclonal antibody, clone SP1, are described.ResultsClone EP1 specifically detects nuclear ER in all tissues examined; cytoplasmic staining was not observed. The analysis shows a high degree of concordance (∼95%) between EP1 and both the ERα component of the Dako ER/PR pharmDx kit and Ventana clone SP1. However, the use of EP1 antibody together with Dako EnVision FLEX detection system resulted in a stronger staining intensity as compared with SP1 antibody using the Ventana ultraView DAB detection system resulting in better ‘ease of use.’ConclusionsThe use of EPI can result in better interpretation of the results of the ER analysis.


2015 ◽  
Vol 4 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Stefan Schulz ◽  
Anika Mann ◽  
Benjamin Novakhov ◽  
Hugh D Piggins ◽  
Amelie Lupp

The vasoactive intestinal peptide receptor 2 (VPAC2) is widely distributed throughout the body and is also overexpressed in a variety of human neoplastic tissues. However, little is known about its precise tissue distribution, regulation and function, which is in part be due to the lack of specific monoclonal anti-VPAC2 antibodies. In this study, we extensively characterised the novel rabbit monoclonal anti-VPAC2 antibody (clone SP235) using transfected cells and mouse, rat and human tissues. SP235 was then subjected to a comparative immunohistochemical study on a series of 167 histological specimens from formalin-fixed, paraffin-embedded human tumours and adjacent normal tissues. SP235 detected a broad band migrating at a molecular weight of 50–70 kDa in western blotting analyses of various mouse tissues as well as VPAC2- but not VPAC1-transfected human embryonic kidney 293 cells. SP235 yielded an efficient immunostaining of distinct cell populations in human tissue samples with a predominance of plasma membrane staining, which was completely abolished by preadsorption with its immunising peptide. SP235 immunohistochemistry detected VPAC2 receptors in lymphocytes present in spleen, tonsils, lymph nodes and Peyer's patches, chief cells of gastric mucosa, exocrine and endocrine pancreas, kidney tubules and blood vessels. In addition, VPAC2 was observed in thyroid, gastric and lung carcinomas, pancreatic adenocarcinomas, sarcomas and neuroendocrine tumours. SP235 may prove of great value in the identification of VPAC2 receptors during routine histopathological examination. VPAC2 visualisation with this simple and rapid immunohistochemical method will facilitate identification of candidate tumours for vasoactive intestinal peptide (VIP)-based diagnostics or therapeutic interventions.


2006 ◽  
Vol 60 (9) ◽  
pp. 1001-1005 ◽  
Author(s):  
S. A. V. Ricardo ◽  
F. Milanezi ◽  
S. T. Carvalho ◽  
D. R. A. Leitao ◽  
F. C. L. Schmitt

Sign in / Sign up

Export Citation Format

Share Document